{"disease":{"id":"bacterial-co-infection","name":"bacterial co infection"},"drugs":{"marketed":[{"drug_id":"ciprofloxacine","indication_name":"Bacterial Corneal Ulcer Infection","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Ciprofloxacine","company_name":"Poitiers University Hospital","drug_phase":"discontinued","molecular_target":"DNA topoisomerase II, DNA gyrase subunit A, DNA gyrase subunit A","drug_class":"","quality_score":null,"revenue":null,"mechanism":""},{"drug_id":"norfloxacin","indication_name":"Bacterial Corneal Ulcer Infection","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Noroxin","generic_name":"NORFLOXACIN","company_name":"","drug_phase":"marketed","molecular_target":"Gamma-aminobutyric acid receptor subunit alpha-1","drug_class":"Quinolone Antimicrobial","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"ofloxacin","indication_name":"Bacterial Corneal Ulcer Infection","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Floxin","generic_name":"OFLOXACIN","company_name":"","drug_phase":"marketed","molecular_target":"Histamine H3 receptor","drug_class":"Quinolone Antimicrobial [EPC]","quality_score":65,"revenue":null,"mechanism":""},{"drug_id":"ciprofloxacin","indication_name":"Bacterial Corneal Ulcer Infection","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cipro","generic_name":"ciprofloxacin","company_name":"Bayer AG","drug_phase":"marketed","molecular_target":"DNA topoisomerase II, DNA gyrase subunit A, DNA gyrase subunit A","drug_class":"Fluoroquinolone antibiotic","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"levofloxacin","indication_name":"Bacterial Corneal Ulcer Infection","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Levaquin","generic_name":"levofloxacin","company_name":"Generic (originally Daiichi Sankyo/J&J)","drug_phase":"marketed","molecular_target":"CAAX prenyl protease 2, Multidrug and toxin extrusion protein 1, Potassium voltage-gated channel subfamily H member 2","drug_class":"Fluoroquinolone Antibacterial [EPC]","quality_score":65,"revenue":null,"mechanism":"Levofloxacin is a fluoroquinolone antibacterial agent."},{"drug_id":"ofloxacine","indication_name":"Bacterial Corneal Ulcer Infection","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Ofloxacine","company_name":"Assistance Publique - Hôpitaux de Paris","drug_phase":"phase_3","molecular_target":"Gamma-aminobutyric acid receptor subunit alpha-2, Histamine H3 receptor, Muscarinic acetylcholine receptor M1","drug_class":"","quality_score":null,"revenue":null,"mechanism":null}],"pipeline":[],"offLabel":[],"totalMarketed":6,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT06769815","title":"Host Immunity, Plasmodium and Pathogens Co-Infections","phase":"NA","overall_status":"NOT_YET_RECRUITING","enrollment_count":2000,"lead_sponsor_name":"Institut Pasteur","has_results":false},{"nct_id":"NCT05336851","title":"Emergency PWAS in Respiratory Infectious Disease","phase":"","overall_status":"RECRUITING","enrollment_count":2000,"lead_sponsor_name":"The University of Hong Kong","has_results":false},{"nct_id":"NCT05939479","title":"Antistaphylococcal Betalactam and Emergence of Resistance","phase":"","overall_status":"COMPLETED","enrollment_count":644,"lead_sponsor_name":"Central Hospital, Nancy, France","has_results":false},{"nct_id":"NCT06131749","title":"Genital Tract Infections, the Vaginal Microbiome and Gestational Age at Birth Among Pregnant Women in South Africa","phase":"","overall_status":"COMPLETED","enrollment_count":603,"lead_sponsor_name":"University of Bern","has_results":false},{"nct_id":"NCT04387799","title":"Determinants of COVID-19 Pneumonia (MC-19)","phase":"","overall_status":"COMPLETED","enrollment_count":520,"lead_sponsor_name":"Catholic University of the Sacred Heart","has_results":false},{"nct_id":"NCT06392568","title":"Epidemiological Features of Emergent Highly Resistant Bacteria in Tunisian Intensive Care Units","phase":"","overall_status":"RECRUITING","enrollment_count":500,"lead_sponsor_name":"Abderrahmane Mami Hospital","has_results":false},{"nct_id":"NCT05412030","title":"A Phase 2 Study to Evaluate the Safety, Tolerability, and Immune Response of AFX3772 Vaccine in Healthy Infants","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":388,"lead_sponsor_name":"GlaxoSmithKline","has_results":false},{"nct_id":"NCT06592586","title":"A Follow-up Trial of GBS-NN/NN2 Vaccine in Healthy Pregnant Women","phase":"PHASE2, PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":338,"lead_sponsor_name":"Minervax ApS","has_results":false},{"nct_id":"NCT05229081","title":"Impact of Pharmacist-led Educational Intervention on Pneumococcal Vaccination Rates in Cancer Patients","phase":"NA","overall_status":"COMPLETED","enrollment_count":228,"lead_sponsor_name":"Hacettepe University","has_results":false},{"nct_id":"NCT02814916","title":"Dalbavancin for the Treatment of Acute Bacterial Skin and Skin Structure Infections in Children, Known or Suspected to be Caused by Susceptible Gram-positive Organisms, Including MRSA","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":199,"lead_sponsor_name":"AbbVie","has_results":true},{"nct_id":"NCT01817075","title":"Chlorhexidine Gluconate Cleansing in Preventing Central Line Associated Bloodstream Infection and Acquisition of Multi-drug Resistant Organisms in Younger Patients With Cancer or Undergoing Donor Stem Cell Transplant","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":177,"lead_sponsor_name":"Children's Oncology Group","has_results":true},{"nct_id":"NCT03252028","title":"Rapid Test for Detection of the Focus of Infection in Post Neurosurgical Patients.","phase":"","overall_status":"UNKNOWN","enrollment_count":150,"lead_sponsor_name":"Fariba Nayeri","has_results":false},{"nct_id":"NCT06548841","title":"Development and Validation of (Bio)Sensors for the Identification of Pathogens","phase":"","overall_status":"COMPLETED","enrollment_count":149,"lead_sponsor_name":"University of Bologna","has_results":false},{"nct_id":"NCT05905055","title":"P3 Study to Assess Efficacy and Safety of Cefepime/Nacubactam and Aztreonam/Nacubactam Versus Best Available Therapy for Adults With Infection Due to Carbapenem Resistant Enterobacterales","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":126,"lead_sponsor_name":"Meiji Seika Pharma Co., Ltd.","has_results":false},{"nct_id":"NCT06155747","title":"Transmission and Acquisition of Nontuberculous Mycobacteria Outbreak Investigation (TrANsMIt)","phase":"","overall_status":"RECRUITING","enrollment_count":100,"lead_sponsor_name":"National Jewish Health","has_results":false},{"nct_id":"NCT04215991","title":"A Study to Assess the Safety, Tolerability, and Pharmacokinetics of Cefiderocol in Hospitalized Pediatric Participants","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":91,"lead_sponsor_name":"Shionogi","has_results":false},{"nct_id":"NCT01970371","title":"A Study of Plazomicin Compared With Colistin in Patients With Infection Due to Carbapenem-Resistant Enterobacteriaceae (CRE)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":69,"lead_sponsor_name":"Achaogen, Inc.","has_results":true},{"nct_id":"NCT04922554","title":"Oral Omadacycline vs. Placebo in Adults With NTM Pulmonary Disease Caused by Mycobacterium Abscessus Complex (MABc)","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":66,"lead_sponsor_name":"Paratek Pharmaceuticals Inc","has_results":true},{"nct_id":"NCT06566495","title":"Microorganisms on Reusable Tourniquets","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":53,"lead_sponsor_name":"Medical University of Gdansk","has_results":false},{"nct_id":"NCT04335539","title":"A Study to Assess the Safety, Tolerability, and Pharmacokinetics of Single and Multiple Doses of Cefiderocol in Hospitalized Pediatric Participants","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":53,"lead_sponsor_name":"Shionogi","has_results":true},{"nct_id":"NCT04921943","title":"Hypertonic Saline for MAC","phase":"PHASE4","overall_status":"RECRUITING","enrollment_count":50,"lead_sponsor_name":"Oregon Health and Science University","has_results":false},{"nct_id":"NCT03446053","title":"A Study to Evaluate the Safety, PK, PD, Immunogenicity of N-Rephasin® SAL200 in Healthy Male Volunteers","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":33,"lead_sponsor_name":"Intron Biotechnology, Inc.","has_results":true},{"nct_id":"NCT03590600","title":"A Single Ascending Dose Study of BTZ043","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":30,"lead_sponsor_name":"Michael Hoelscher","has_results":false},{"nct_id":"NCT05611892","title":"Biodistribution and Pathophysiology Study of 18F-Fluorodeoxysorbitol (18F-FDS) in Diseased Patients","phase":"","overall_status":"COMPLETED","enrollment_count":16,"lead_sponsor_name":"Johns Hopkins University","has_results":false},{"nct_id":"NCT04685720","title":"A Pilot Study to Assess the Effect of Intermittent iNO on the Treatment of NTM Lung Infection in CF and Non-CF Patients","phase":"NA","overall_status":"COMPLETED","enrollment_count":15,"lead_sponsor_name":"Beyond Air Inc.","has_results":false},{"nct_id":"NCT06262282","title":"Mycobacteriophage Treatment of Non-tuberculosis Mycobacteria","phase":"","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":10,"lead_sponsor_name":"National Jewish Health","has_results":false},{"nct_id":"NCT04664075","title":"Predicting Severity and Disease Progression in Influenza-like Illness (Including COVID-19)","phase":"","overall_status":"TERMINATED","enrollment_count":8,"lead_sponsor_name":"Imperial College London","has_results":true},{"nct_id":"NCT04783727","title":"PredictEndTB Signature for Individualizing Treatment in Multidrug-Resistant Tuberculosis","phase":"NA","overall_status":"TERMINATED","enrollment_count":4,"lead_sponsor_name":"Research Center Borstel","has_results":false},{"nct_id":"NCT04874948","title":"Absorption, Elimination and Safety of 14C-labeled Radioactive BTZ-043, a New Compound in TB Treatment","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":4,"lead_sponsor_name":"Michael Hoelscher","has_results":true}],"total":29},"guidelines":[],"source":"Drug Landscape verified database"}